Deals
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
FEATURED STORIES
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The news comes months after the company closed a $63 million Series B and inlicensed RAIN-32 from Daiichi Sankyo.
Eloxx Pharma has experienced a string of changes over the past year, coming to a head with today’s announcement that the company will be acquiring early-stage biotech Zikani Therapeutics in an all-stock deal.
Under the terms of the deal, Amgen is buying all outstanding shares of Rodeo with a $55 million upfront payment. In addition, there are potential milestone payments that could hit $666 million in cash.
Illumina plans to continue to pursue its acquisition of Grail Inc. despite the objection of the U.S. Federal Trade Commission.
This morning, Ikena Oncology, Design Therapeutics and Edgewise Therapeutics began trading on the exchange.
Several new initial public offering (IPO) announcements have been made by international and U.S.-based biopharmaceutical and biotechnology companies in the past couple of days.
This week, four companies set sights on listing their shares on the stock market in hopes of raising significant funds to support the development of their pipelines and businesses.
It’s been another strong week of biopharma companies making their debut on a stock exchange. Over the past 48 hours, three companies, Finch Therapeutics, Connect Biopharma and Gain Therapeutics, all made their debut on the Nasdaq.
On March 4, 2021, Amgen announced that they had acquired Five Prime Therapeutics for $38 per share in cash, which is an equity value of about $1.9 billion.
The goal is to “identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.”